

# Jean-Jacques Grob

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714178/publications.pdf>

Version: 2024-02-01

95  
papers

31,585  
citations

44069

48  
h-index

48315

88  
g-index

97  
all docs

97  
docs citations

97  
times ranked

25281  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	27.0	4,074
2	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	27.0	3,589
3	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 358-365.	13.7	2,691
4	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	27.0	2,484
5	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
6	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441
7	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	13.7	1,175
8	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	27.0	1,140
9	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgBT /Ove	10.7	1,093
10	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1480-1492.	10.7	1,089
11	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017, 390, 1853-1862.	13.7	1,032
12	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2019, 20, 1239-1251.	10.7	812
13	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2019, 20, 1083-1097.	10.7	611
14	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	4.4	563
15	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 863-873.	10.7	561
16	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
17	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
18	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	1.6	445

#	ARTICLE	IF	CITATIONS
19	Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 1118-1125.	1.6	439
20	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15003.	30.5	417
21	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017, 136, 2085-2087.	1.6	364
22	Adjuvant nivolumab versus ipilimumab in resected stage IIIA-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	10.7	330
23	Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study. <i>Journal of Investigative Dermatology</i> , 2015, 135, 67-75.	0.7	307
24	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.	7.1	304
25	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	7.1	287
26	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	10.7	266
27	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1718-1729.	13.7	236
28	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
29	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	1.6	192
30	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
31	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
32	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154
33	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
34	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	2.8	132
35	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	7.1	131
36	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	10.7	131

#	ARTICLE	IF	CITATIONS
37	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
38	Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. <i>Annals of Oncology</i> , 2017, 28, 1137-1144.	1.2	94
39	Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: A series of 106 patients without whole-brain radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 809-816.	0.8	90
40	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for BRAF V600E Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
41	Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: A randomized study. <i>International Journal of Cancer</i> , 2006, 118, 2276-2280.	5.1	76
42	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	2.8	76
43	On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2014, 25, 2086-2091.	1.2	72
44	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
45	Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. <i>European Journal of Cancer</i> , 2017, 84, 44-54.	2.8	67
46	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	2.8	64
47	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	2.4	59
48	SARS-CoV-2 infection presenting as a febrile rash. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e304-e306.	2.4	59
49	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Ov		52
50	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. <i>Annals of Oncology</i> , 2014, 25, 1428-1436.	1.2	45
51	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
52	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
53	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	10.9	34
54	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33

#	ARTICLE	IF	CITATIONS
55	Macrophage activation syndrome: A new complication of checkpoint inhibitors. <i>European Journal of Cancer</i> , 2017, 77, 88-89.	2.8	31
56	Diabetes and Blood Glucose Disorders Under Anti-PD1. <i>Journal of Immunotherapy</i> , 2018, 41, 232-240.	2.4	27
57	Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy. <i>European Journal of Cancer</i> , 2020, 135, 52-61.	2.8	24
58	Evidence of a Limited Intra-Individual Diversity of Nevi: Intuitive Perception of Dominant Clusters Is a Crucial Step in the Analysis of Nevi by Dermatologists. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2355-2361.	0.7	23
59	The evolving field of Dermatocancerology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV and UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
60	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947.	1.2	21
61	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014, 120, 2016-2024.	4.1	19
62	Adverse events 2.0 – Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	2.8	19
63	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214.	5.2	18
64	Prognostic and predictive value of $\beta$ -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	2.8	18
65	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	2.8	17
66	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018, 28, 775-783.	0.6	16
67	Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. <i>European Journal of Cancer</i> , 2014, 50, 1120-1124.	2.8	15
68	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <i>ESMO Open</i> , 2017, 2, e000203.	4.5	15
69	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2149-2153.	2.4	14
70	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	2.8	13
71	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021, 32, 542-551.	1.2	13
72	Cognitive training with photographs as a new concept in an education campaign for self-detection of melanoma: a pilot study in the community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1099-1103.	2.4	12

#	ARTICLE	IF	CITATIONS
73	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 700-710.	1.5	12
74	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
75	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	2.7	11
76	Molecular characterization of fast-growing melanomas. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 312-321.	1.2	11
77	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1949-1956.	2.4	10
78	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage) Tj ETQq0 0 0 rgBT /Overlock 10 Tf IIIb study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021, 154, 57-65.	2.8	9
79	Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with <i>TP53<sup>WT</sup></i> Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9506-9506.	1.6	9
80	Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire. <i>Quality of Life Research</i> , 2021, 30, 1225-1231.	3.1	8
81	Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision. <i>PLoS ONE</i> , 2017, 12, e0176080.	2.5	8
82	Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9500-LBA9500.	1.6	7
83	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF<sup>V600</sup></i>-positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	1.6	6
84	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1119-1132.	2.4	5
85	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	1.0	4
86	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. <i>Blood</i> , 2021, 138, 790-790.	1.4	4
87	Antiâ€‹i>N</i>â€‹methylâ€‹scp>D</scp>â€‹aspartate receptor encephalitis during treatment with adalimumab for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e591-e593.	2.4	3
88	Learning from examples to automatically cluster pigmented skin lesions. , 2013, , .		1
89	Reply to E. Hindiâ€‹©. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	1.6	1
90	The â€œGreat Debateâ€‹at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	4.4	1

#	ARTICLE	IF	CITATIONS
91	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. <i>European Journal of Cancer</i> , 2021, 156, S23-S24.	2.8	1
92	Le dermatologue et le mélanome. D'œ venons-nous? Oœ sommes-nous? Oœ allons-nous?. <i>Annales De Dermatologie Et De Venereologie</i> , 2012, 139, B18-B19.	1.0	0
93	On-demand Gamma Knife combined with BRAF inhibitors for the treatment of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9083-9083.	1.6	0
94	Risk factors of fast growing melanomas in a French prospective cohort.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21042-e21042.	1.6	0
95	Methotrexate for idiopathic chronic eczematous eruption of aging. <i>European Journal of Dermatology</i> , 2021, 31, 839-841.	0.6	0